CryoPort, Inc. (CYRX): Price and Financial Metrics
CYRX Stock Summary
- CYRX's price/sales ratio is 34.18; that's higher than the P/S ratio of 92.97% of US stocks.
- With a year-over-year growth in debt of 2,627.31%, Cryoport Inc's debt growth rate surpasses 99.22% of about US stocks.
- As for revenue growth, note that CYRX's revenue has grown 131.86% over the past 12 months; that beats the revenue growth of 95.54% of US companies in our set.
- Stocks with similar financial metrics, market capitalization, and price volatility to Cryoport Inc are NVRO, EKSO, WEI, ECOR, and IMMR.
- CYRX's SEC filings can be seen here. And to visit Cryoport Inc's official web site, go to www.cryoport.com.
CYRX Stock Price Chart Interactive Chart >
CYRX Price/Volume Stats
|Current price||$55.01||52-week high||$84.97|
|Prev. close||$59.01||52-week low||$13.01|
|Day high||$60.19||Avg. volume||757,883|
|50-day MA||$61.33||Dividend yield||N/A|
|200-day MA||$45.44||Market Cap||2.18B|
CryoPort, Inc. (CYRX) Company Bio
CryoPort, Inc. provides cryogenic logistics solutions to the life sciences industry in the United States, Europe, Asia, and internationally. The company offers Cryoportal, a cloud-based logistics management software that automates the entry of orders, prepares customs documentation, and facilitates status and location monitoring of shipped orders while in transit; and CryoPort Express Shippers, which are cryogenic dry vapor shippers that use liquid nitrogen contained inside a vacuum insulated vessel, which serves as a refrigerant to provide stable storage temperatures. The company was founded in 1999 and is based in Irvine, California.
CYRX Latest News Stream
|Loading, please wait...|
CYRX Latest Social Stream
View Full CYRX Social Stream
Latest CYRX News From Around the Web
Below are the latest news stories about Cryoport Inc that investors may wish to consider to help them evaluate CYRX as an investment opportunity.
Cryoport, Inc. (CYRX) Q4 2020 Earnings Conference Call March 1, 2021 5:00 PM ET Company Participants Todd Fromer - Managing Partner, KCSA Jerrell Shelton - Chief Executive Officer Robert Stefanovich - Chief Financial Officer Mark Sawicki - Chief Scientific Officer Thomas Heinzen - Vice President, Corporate Development & Investor Relations...
CryoPort outperformed sales expectations for the fourth quarter amid a rebound in clinical trial activity from the COVID-19 impact. Shares of the temperature-controlled logistics and biostorage services provider closed more than 5% higher on March 1. Meanwhile, CryoPort (CYRX) posted a 4Q net loss of $0.26 per share due to higher operating costs. Analysts had forecasted a net loss $0.11 per share. Revenue during the reported quarter increased 423% year-over-year to hit $48.36 million, topping analysts’ estimates of $43.95 million. Biopharma revenue jumped 378% year-over-year to $39.3 million. Revenue from the animal health segement ballooned 2363% year-over-year to $7.
CryoPort, Inc. (CYRX) delivered earnings and revenue surprises of -86.67% and 11.71%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced financial results for the three- and twelve-month periods ended December 31, 2020.
NEW YORK, NY / ACCESSWIRE / March 1, 2021 / CryoPort, Inc. (NASDAQ:CYRX) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on March 1, 2021 at 5:00 PM Eastern Time.
CYRX Price Returns
Continue Researching CYRXWant to do more research on Cryoport Inc's stock and its price? Try the links below:
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!